NCT07193394
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07193394
Title Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer (H3RAKLES)
Acronym H3RAKLES
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut Curie
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.